Genomic landscape and evolutionary dynamics of <i>RAS</i> alterations in glioma: A large-scale clinicopathologic analysis.
Journal of Clinical Oncology · 2026-05-28
A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an <i>IDH1/2</i> mutation (INDIGO): Updated efficacy and safety.
Journal of Clinical Oncology · 2026-05-27
Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study.
Journal of Clinical Oncology · 2026-05-27
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data
Journal of Clinical Oncology · 2026-05-22
Primitive neuronal component is a frequent finding among IDH-mutant astrocytomas with RB1 alterations
Acta Neuropathologica · 2026-04-19
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
Cancer Cell · 2026-04-18
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Journal of Clinical Oncology · 2026-04-14 · 1 citations
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
Cancer Cell · 2026-03-26 · 2 citations
Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas
JCO Precision Oncology · 2026-02-01
Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma
Neuro-Oncology · 2026-01-16
Supplementary Tables S1-S2 from Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology
2025-12-11
10204-CS-21 Exploratory analyses from the INDIGO study on the mechanism of seizure control by vorasidenib through tumor volume reduction
Neuro-Oncology Advances · 2025-12-01 · 1 citations
10197-CS-19 A global, randomized, double-blinded, Phase 3 study of Vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): updated data from the Japan subgroup analysis
Neuro-Oncology Advances · 2025-12-01
Co-Hyperpolarized Dehydroascorbate and Pyruvate MRI Predicts Treatment Response in GlioblastomaPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-13
Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)
Blood · 2025-11-03 · 1 citations
Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)
Blood · 2025-11-03
IMG-118. Glioblastoma distant recurrences preferentially occur along white matter tracts mapped using probabilistic diffusion tractography
Neuro-Oncology · 2025-11-01
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Neuro-Oncology · 2025-11-01 · 1 citations
CTNI-49. IBRUTINIB IN COMBINATION WITH RITUXIMAB, METHOTREXATE (MTX), VINCRISTINE, AND PROCARBAZINE (R-MPV/I) FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (PCNSL)
Neuro-Oncology · 2025-11-01
CTNI-34. PHASE 1B SAFETY RESULTS OF VORASIDENIB IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH MUTANT IDH1 OR IDH2 GLIOMA
Neuro-Oncology · 2025-11-01